Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer

BACKGROUND: We aimed to evaluate the ability of circulating cell-free methylated SETP9 DNA (mSEPT9) to identify recurrence and to determine its clinical utility in adjuvant chemotherapy (ACT) regimen decisions. MATERIAL/METHODS: This study enrolled 426 patients with stage II–III CRC who received rad...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Zhen, Wang, Shuyuan, Ni, Kemin, Zhan, Yixiang, Ma, Hong, Liu, Xinyu, Xin, Ran, Zhou, Xingyu, Liu, Zhaoce, Zhao, Xuanzhu, Yin, Xin, Ping, Hangyu, Liu, Yaohong, Wang, Wanting, Yan, Suying, Han, Qiurong, Cui, Wei, Zhang, Xipeng, Zhang, Qinghuai, Zhang, Chunze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503252/
https://www.ncbi.nlm.nih.gov/pubmed/36117308
http://dx.doi.org/10.12659/MSM.937757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503252/
https://www.ncbi.nlm.nih.gov/pubmed/36117308
http://dx.doi.org/10.12659/MSM.937757

Ejemplares similares